- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07657728
Group Positive Psychology-Based Program for Fear of Breast Cancer Recurrence
The Effect of a Positive Psychology-Based Educational Program on Fear of Breast Cancer Recurrence in Women Attending Mirdamad Clinic in Gorgan, Iran: A Randomized Controlled Trial
The goal of this clinical trial is to learn whether a group positive psychology-based educational program can reduce fear of cancer recurrence in women with a history of breast cancer who have completed primary treatment (surgery, chemotherapy, and radiotherapy).
The main question it aims to answer is:
Does an 8-week online positive psychology program reduce fear of cancer recurrence scores measured by the Fear of Cancer Recurrence Inventory (FCRI) compared to no intervention? Researchers will compare the intervention group (received 8 weeks of positive psychology training) to the control group (received no intervention during the study period) to see if the positive psychology program significantly reduces fear of cancer recurrence.
Participants will:
Complete online demographic and baseline Fear of Cancer Recurrence Inventory (FCRI) questionnaires (approximately 20 minutes) If assigned to the intervention group: Attend eight weekly 90-minute online positive psychology sessions based on Seligman's model via Skype Complete home exercises between sessions (e.g., recording three good things daily, writing a gratitude letter, practicing savoring techniques) Complete the FCRI questionnaire again immediately after the final intervention session.
If assigned to the control group: Receive no intervention during the study period and complete the FCRI questionnaire at the same time points as the intervention group; offered the same positive psychology training two months after the study ends
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This study was a parallel-group, randomized controlled trial with a pretest-posttest design, conducted between July and September 2023 at Mirdamad Clinic in Gorgan, Iran. The study aimed to evaluate the effectiveness of a group positive psychology-based educational program on fear of cancer recurrence in women with a history of breast cancer.
Theoretical Framework:
The intervention was grounded in Seligman's positive psychology theory, which emphasizes the cultivation of positive emotions, engagement, relationships, meaning, and accomplishment (PERMA model). The program focused on identifying and using signature character strengths, gratitude, savoring, hope and optimism, post-traumatic growth through expressive writing, forgiveness, and altruism.
Intervention Protocol:
Participants assigned to the intervention group received eight weekly 90-minute online sessions delivered via the Skype application. Each session consisted of 45 minutes dedicated to reviewing homework from the previous session and 45 minutes focused on discussion and practice of new skills. A PDF booklet summarizing session content and home exercises was sent to participants via WhatsApp Messenger after each session.
The session content was as follows:
Session 1 (Introduction to Positive Psychology and Signature Strengths): Participants were introduced to positive psychology concepts and completed an online VIA-IS (Values in Action Inventory of Strengths) questionnaire to identify their top five signature strengths. Each participant shared a personal story illustrating one of their signature strengths with the group.
Session 2 (Three Good Things): Participants were instructed to record three positive events that occurred each day for one week and to reflect on the causes of these events. This exercise aimed to counter negativity bias and cultivate gratitude.
Session 3 (Savoring): Participants learned and practiced techniques for mindfully attending to and prolonging positive experiences, including sharing positive events with others, memory building, self-congratulation, and absorption in positive activities.
Session 4 (Hope and Optimism): Participants completed a guided visualization exercise identifying "closed doors" (past disappointments or failures) and "opened doors" (new opportunities that emerged). This exercise aimed to reframe negative experiences and foster hope.
Session 5 (Expressive Writing for Post-Traumatic Growth): Participants wrote about their most difficult life experience for 15-20 minutes daily for four consecutive days. This exercise aimed to process trauma and identify post-traumatic growth.
Session 6 (Gratitude Letter): Participants wrote a detailed letter of gratitude to someone who had helped them but whom they had never properly thanked. They were instructed to deliver the letter in person and read it aloud to the recipient.
Session 7 (Forgiveness): Participants completed a structured forgiveness exercise identifying a person toward whom they held a grudge, listing that person's positive attributes, and reflecting on the emotional impact of holding the grudge.
Session 8 (Review and Gift of Time): The final session reviewed all previous skills and concepts. Participants were instructed to give a "gift of time" to someone important by using one of their signature strengths to perform an act of kindness or service.
Control Group:
Participants assigned to the control group received no intervention during the study period. After the two-month follow-up assessment, they were offered the same positive psychology training as a courtesy.
Study Procedures:
After obtaining ethics approval and clinic permissions, the researcher screened patients at Mirdamad Clinic by reviewing medical records. Eligible women were contacted by telephone, provided with an explanation of the study objectives, and invited to participate. All participants provided written informed consent online.
Participants completed the demographic information form and the Fear of Cancer Recurrence Inventory (FCRI) online at baseline. They were then randomly assigned to the intervention or control group using block randomization with a block size of four. The randomization sequence was generated by an individual independent of the primary researcher, and group allocations were concealed in opaque, unlabeled envelopes until the start of the intervention.
The intervention group received the eight-week online positive psychology program as described above. Both groups completed the FCRI again immediately after the final intervention session. The outcome assessor was blinded to group allocation.
Intervention Fidelity:
To ensure intervention fidelity, all sessions were recorded and reviewed by an external monitor who was unaware of group assignment. The monitor used a checklist based on the content of each session to verify that all key components were delivered as planned. Additionally, the researcher completed a specialized online training course in positive psychology under the supervision of a doctoral-level psychologist before delivering the intervention.
Data Quality and Management:
Data were collected online using structured forms. The demographic information form and FCRI questionnaire were administered via an online platform with required fields to prevent missing data. Participant responses were automatically recorded in a secure database accessible only to the research team.
Normality of continuous variables was assessed using the Shapiro-Wilk test before statistical analysis. Outliers were not removed unless attributable to data entry error. No imputation methods were applied for missing data, as the final analysis included only participants with complete pre- and post-intervention data.
Statistical Analysis Plan:
Data were analyzed using SPSS version 18 (SPSS Inc., Chicago, IL, USA). Descriptive statistics, including mean, standard deviation, frequency, and percentage, were calculated for demographic and clinical variables. Between-group comparisons of continuous variables at baseline and post-intervention were performed using independent t-tests for normally distributed data and the Mann-Whitney U test for non-normally distributed data. Within-group comparisons (pre- to post-intervention) were conducted using paired t-tests for normally distributed data and the Wilcoxon signed-rank test for non-normally distributed data. Categorical variables were compared using the chi-square test or Fisher's exact test, as appropriate.
To adjust for baseline differences and control for potential confounders, analysis of covariance (ANCOVA) was performed on post-intervention total FCRI scores, with pre-intervention scores as the covariate. Subgroup analyses by ethnicity were also conducted. Effect sizes (partial eta squared) were calculated from ANCOVA results. The significance level for all statistical tests was set at p < 0.05.
Sample Size Justification:
The sample size was calculated based on a previous study by Ahmadi Qaragezlou et al. (2020), using the reported means and standard deviations for fear of cancer recurrence (intervention group: 0.9 ± 0.5; control group: 0.5 ± 0.2). Applying the formula for two independent groups with a 95% confidence level (Z₁-α/₂ = 1.96), 80% statistical power (Z₁-β = 0.84), and accounting for a 22% prevalence of fear of cancer recurrence and a 10% anticipated attrition rate, the required sample size was determined to be 19 participants per group, totaling 38 participants.
Participant Compensation:
As a token of appreciation, each participant received a certificate for a tree restored in the Zagros forests, symbolizing their contribution to environmental preservation.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Golestan Province
-
Gorgan, Golestan Province, Iran
- Mirdamad Clinic
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Confirmed diagnosis of breast cancer (stages 1 to 3) by a specialist physician
- Completion of all treatment phases, including surgery, chemotherapy, and radiotherapy
- No documented history of personality or psychological disorders based on medical records
- No current use of psychiatric or sedative medications
- No prior participation in a psychological intervention similar to the one studied
- Married
- Residing in Golestan Province, Iran
- At least elementary school education
- Access to an electronic device (computer, tablet, or smartphone) to participate in online sessions
- Willing to provide written informed consent
Exclusion Criteria:
- Diagnosis of metastatic breast cancer
- Diagnosis of recurrent breast cancer during the study period
- Current use of alcohol, tobacco, or recreational drugs
- Participation in yoga or meditation classes prior to the study
- Hearing or speaking problems that would prevent participation in online sessions
- Concurrent participation in other psychosocial programs or psychotherapy
- Absence from more than two intervention sessions (for participants assigned to the intervention group)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Positive Psychology Intervention
Participants received 8 weekly 90-minute online positive psychology sessions
|
Eight 90-minute weekly online group sessions based on Seligman's positive psychology model, delivered via Skype.
Session topics include: introduction to positive psychology and signature strengths; three good things exercise; savoring techniques; hope and optimism; expressive writing for post-traumatic growth; gratitude letter; forgiveness; and review with gift of time.
A PDF booklet containing session content and home exercises was sent to participants via WhatsApp after each session.
|
|
Nessun intervento: Control
Participants received no intervention during the study period
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from Baseline in Total Fear of Cancer Recurrence Inventory (FCRI) Score at 8 Weeks
Lasso di tempo: Baseline and immediately after the final intervention session (8 weeks from baseline)
|
The Fear of Cancer Recurrence Inventory (FCRI) is a 42-item self-report questionnaire that assesses fear of cancer recurrence over the preceding month.
Each item is rated on a five-point Likert scale from 0 ("not at all" or "never") to 4 ("very much" or "always").
One item ("I believe that I am cured and my disease will not return") is reverse-scored.
Total scores range from 0 to 168.
Higher scores indicate greater fear of cancer recurrence.
Change from baseline to 8 weeks (post-intervention) is reported.
A negative change score indicates reduction in fear of cancer recurrence.
|
Baseline and immediately after the final intervention session (8 weeks from baseline)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from Baseline in FCRI Triggers Subscale Score at 8 Weeks
Lasso di tempo: Baseline and 8 weeks (post-intervention)
|
The triggers subscale of the Fear of Cancer Recurrence Inventory (FCRI) consists of 6 items assessing potential triggers that activate fear of cancer recurrence.
Each item is scored from 0 to 4. Scores range from 0 to 24.
Higher scores indicate greater fear triggered by cancer-related stimuli.
Change from baseline to 8 weeks is reported; negative change indicates reduction.
|
Baseline and 8 weeks (post-intervention)
|
|
Change from Baseline in FCRI Severity Subscale Score at 8 Weeks
Lasso di tempo: Baseline and 8 weeks (post-intervention)
|
The severity subscale of the Fear of Cancer Recurrence Inventory (FCRI) consists of 8 items assessing the presence and severity of intrusive thoughts associated with fear of cancer recurrence.
Each item is scored from 0 to 4. Scores range from 0 to 32.
Higher scores indicate greater severity of fear.
Change from baseline to 8 weeks is reported; negative change indicates reduction.
|
Baseline and 8 weeks (post-intervention)
|
|
Change from Baseline in FCRI Psychological Distress Subscale Score at 8 Weeks
Lasso di tempo: Baseline and 8 weeks (post-intervention)
|
The psychological distress subscale of the Fear of Cancer Recurrence Inventory (FCRI) consists of 9 items assessing emotional dysfunction associated with fear of cancer recurrence.
Each item is scored from 0 to 4. Scores range from 0 to 36.
Higher scores indicate greater psychological distress.
Change from baseline to 8 weeks is reported; negative change indicates reduction.
|
Baseline and 8 weeks (post-intervention)
|
|
Change from Baseline in FCRI Functional Impairment Subscale Score at 8 Weeks
Lasso di tempo: Baseline and 8 weeks (post-intervention)
|
The functional impairment subscale of the Fear of Cancer Recurrence Inventory (FCRI) consists of 9 items assessing the effect of fear of cancer recurrence on functional areas of life.
Each item is scored from 0 to 4. Scores range from 0 to 36.
Higher scores indicate greater functional impairment.
Change from baseline to 8 weeks is reported; negative change indicates improvement.
|
Baseline and 8 weeks (post-intervention)
|
|
Change from Baseline in FCRI Coping Strategies Subscale Score at 8 Weeks
Lasso di tempo: Baseline and 8 weeks (post-intervention)
|
The coping strategies subscale of the Fear of Cancer Recurrence Inventory (FCRI) consists of 4 items assessing strategies used to address fear of cancer recurrence.
Each item is scored from 0 to 4. Scores range from 0 to 16.
Higher scores indicate greater use of coping strategies.
Change from baseline to 8 weeks is reported.
|
Baseline and 8 weeks (post-intervention)
|
|
Change from Baseline in FCRI Insight Subscale Score at 8 Weeks
Lasso di tempo: Baseline and 8 weeks (post-intervention)
|
The insight subscale of the Fear of Cancer Recurrence Inventory (FCRI) consists of 3 items assessing self-blame against the intensity of fear of cancer recurrence.
Each item is scored from 0 to 4. Scores range from 0 to 12. Higher scores indicate greater insight into the excessiveness of fear.
Change from baseline to 8 weeks is reported; negative change indicates reduction.
|
Baseline and 8 weeks (post-intervention)
|
|
Change from Baseline in FCRI Reassurance Subscale Score at 8 Weeks
Lasso di tempo: Baseline and 8 weeks (post-intervention)
|
The reassurance subscale of the Fear of Cancer Recurrence Inventory (FCRI) consists of 3 items assessing reassurance-seeking behavior through examination and medical counseling.
Each item is scored from 0 to 4. Scores range from 0 to 12. Higher scores indicate greater reassurance-seeking behavior.
Change from baseline to 8 weeks is reported; negative change indicates reduction.
|
Baseline and 8 weeks (post-intervention)
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- IR. GOUMS. REC. 1402. 077
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Recidiva del cancro
-
Zeba Ahmad, Ph.D.American Cancer Society, Inc.ReclutamentoCaregiving for CancerStati Uniti
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
Institut Cancerologie de l'OuestAttivo, non reclutanteQualità della vita al lavoro | Professionisti paramedici | Toccare Massaggio | Cancer CenterFrancia
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
Yonsei UniversityNon ancora reclutamentoRAS/BRAF Wild-Type Advanced Cancer MathementCorea, Repubblica di
-
NRG OncologyNational Cancer Institute (NCI)CompletatoCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea del Sud
-
Jonsson Comprehensive Cancer CenterReclutamentoAdenocarcinoma prostatico | Cancro alla prostata in stadio II AJCC v8 | Fase I Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Jonsson Comprehensive Cancer CenterNovartis PharmaceuticalsReclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Second Affiliated Hospital, School of Medicine,...Attivo, non reclutanteElettroacopuntura combinata con paclitaxel legato alla proteina e anticorpo PD-1 per il trattamento di seconda linea di HER2 negativo, PMMR/MSS Advanced Gastric CancerCina
Prove cliniche su Positive Psychology-Based Educational Program
-
Cairo UniversityCompletatoSclerosi multipla recidivante-remittenteEgitto